Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Four-Period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (10mg and 30mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Volunteers Aged 18 to 45 Years

Next Previous
Search
Trial Profile

A Phase I, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Four-Period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (10mg and 30mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Volunteers Aged 18 to 45 Years

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zibotentan (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca

    • Most Recent Events

    • 05 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Aug 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top